Supplementary Table 1. Demographic and clinical data of patients with CKD

Patient #	Gender	Age	Diagnosis	Serum creatinine (mg/dl)	Proteinuria (g/24h)	Wnt9a staining
1	M	42	Renal carcinoma	0.92	0.08	(-) *
2	F	48	Renal carcinoma	1.09	0.11	(-)
3	F	36	FSGS	0.50	1.46	(++)
4	F	28	FSGS	0.70	1.07	(++)
5	F	32	IgAN	0.81	1.11	(++)
6	F	34	IgAN	0.67	0.36	(++)
7	F	52	IgAN	3.34	4.34	(++)
8	M	43	IgAN	1.50	0.74	(+++)
9	M	19	IgAN	0.69	0.34	(++)
10	M	24	IgAN	0.87	0.32	(++)
11	M	33	IgAN	1.01	0.44	(++)
12	M	38	IgAN	1.76	5.93	(++) *
13	F	32	IgAN	0.66	0.82	(++)
14	F	55	LN	0.78	1.83	(++) *
15	F	18	LN	0.83	5.04	(++)
16	M	31	LN	1.65	14.6	(+++)
17	M	18	LN	0.89	7.34	(++)
18	F	36	LN	0.57	0.11	(++)
19	F	36	MCD	0.89	0.76	(+) *
20	M	30	MCD	1.33	13.63	(++)
21	M	16	MCD	0.63	5.19	(++)
22	F	36	MCD	0.60	7.64	(++)
23	M	33	MCD	0.71	9.91	(+)
24	M	30	MCD	0.76	7.36	(++)
25	M	23	MCD	0.97	6.68	(+)
26	M	17	MCD	1.01	5.44	(++)

27	M	43	MN	0.98	10.61	(+++)
28	M	67	MN	1.03	2.34	(+++)
29	M	16	MN	0.95	0.28	(+)
30	F	49	MN	0.78	2.05	(+)
31	M	63	MN	0.85	12.42	(++)
32	F	20	MN	0.42	4.36	(+++) *
33	M	43	MN	0.68	0.97	(++)
34	F	30	MsPGN	0.64	0.22	(++)
35	F	34	MsPGN	0.71	1.6	(++)
36	M	53	DN	3.01	0.65	(++) *
37	M	47	DN	1.33	4.11	(+++)

*denote images were presented in Figure 1. M, male; F, female; FSGS, focal segmental glomerular sclerosis; IgAN, IgA nephropathy; LN, lupus nephritis; MCD, minimal change disease; MN, membranous nephropathy; MsPGN, mesangial proliferative glomerulonephritis; DN, diabetic nephropathy. The intensity of Wnt9a staining was graded as negative (-), weak staining (+), moderate staining (++), and strong staining (+++).

Supplementary Table 2. Nucleotide sequences of the primers used for PCR

Gene	**Primer Sequence 5' to 3'**		**Product Size (bp)**
	Forward	**Reverse**	
$p16^{INK4A}$-Human	acttcaggggtgccacattc	cgaccctgtccctcaaatcc	126
$p16^{INK4A}$-Mouse	catctggagcagcatggagtc	gcaccgtagttgagcagaaga	192
MMP-7-Mouse	taggcggagatgctcacttt	ttctgaatgcctgcaatgtc	211
PAI-1-Mouse	cacaggcactgcaaaaggtc	tgtgccgaaccacaaagaga	141
α-SMA-Rat	catcgtgttggattctgggg	gtcacgaaggaatagccacg	156
cyclin D1-Rat	tcaagtgtgacccggactg	gaccagcttcttcctccactt	138
β-actin-Mouse	gagcgcaagtactctgtgtg	aacgcagctcagtaacagtc	152
β-actin-Human	ctcaccatggatgatgatatcgc	aggaatccttctgacccatgc	163
β-actin-Rat	aagatcaagatcattgctcctcctg	cgcagctcagtaacagtccg	174